Ritter Pharmaceuticals (RTTR) Flails on Study Results

Ritter Pharmaceuticals Inc (NASDAQ: RTTR) dropped 20.5% to $1.55 after the company reported topline results from its Ph2b/3 study for lactose intolerance treatment RP-G28. Share volume was 1.3 million, compared to an all-day average of 148,000